A supplier suspends shipping to Ireland after 15 consecutive customs detentions
The route did not close because of a rule about peptides.
Archive — March 2025
Page 2 of 5 of this archive, newest first.
STEP 3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Canada health authority warns on falsified liraglutide pens
Reported from the analysis, not from a warning notice.
The consolidator trading as Meridian Freight Partners closes after 5 years
A proper account of an operation that existed, and of what closing it cost.
Why your laboratory interval differs from the one in the textbook
The arithmetic of the reference change value, worked for the analytes that matter here.
How a claim degrades between the bench and the listing
The Journal does not treat a badge as evidence and states so wherever it reports one.
What a 26% rise in coupling-reagent prices does to a 15 mg vial
Follow the resin, not the catalogue.
A supplier suspends shipping to New Zealand after 6 consecutive customs detentions
The route did not close because of a rule about peptides.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Falling ferritin is not always falling iron
Three different explanations for the same abnormal number, and how to tell them apart.
Why the bone question is harder than the muscle question
Density is a proxy for strength and an imperfect one, particularly when soft-tissue thickness over the measurement site is changing.
The sample is not the batch
Chain of custody, in a regulated setting, begins at sampling. Here it begins when the package arrives.
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Guangzhou: 7 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Six words a verification badge would need to mean anything
Every step between the laboratory report and the product page removes information, and the badge is the last step.
A shortage listing ends. 9 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Independent analysis puts a WWB semaglutide lot at 96.9%, against 93.3% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
STEP 3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The incidence tables, read line by line
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
The limits of mechanism: why receptor data will not tell you who responds
Receptor pharmacology is strong on average effects and almost silent on individual variation. That gap is where most reader questions live.
Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
SURPASS-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Portugal declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The submitted sample: the weakest link in the whole system
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
Five lines that would change what a certificate is worth
None of what this piece asks for is commercially sensitive, and all of it is already known to whoever released the batch.
A shortage listing ends. 12 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
What a 9% rise in coupling-reagent prices does to a 30 mg vial
Follow the resin, not the catalogue.
Australia caps exenatide prescribing to 15 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Tolerability is the ceiling, and the ceiling is personal
An effect is dose-limiting when it prevents adequate intake, prevents normal activity, or produces a risk of its own. Discomfort alone is not the test.
The supply gap as a clinical event
The trials studied planned withdrawal. Almost nobody stops that way.
TRIUMPH-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
TRIUMPH-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Portugal declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The consolidator trading as Meridian Freight Partners enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Antiemetics, laxatives and the thin literature underneath them
Constipation is the most tractable of the effects and the most consistently under-managed.
Not everybody regains at the same rate, and nobody knows why
What returns, in what order, and how much of the benefit survives.